1.90
-0.18(-8.65%)
Currency In USD
| Previous Close | 2.08 |
| Open | 2.05 |
| Day High | 2.13 |
| Day Low | 1.9 |
| 52-Week High | 33.1 |
| 52-Week Low | 1.04 |
| Volume | 1.39M |
| Average Volume | 6.14M |
| Market Cap | 33.76M |
| PE | -0.37 |
| EPS | -5.08 |
| Moving Average 50 Days | 2.63 |
| Moving Average 200 Days | 3.73 |
| Change | -0.18 |
If you invested $1000 in BioVie Inc. (BIVI) since IPO date, it would be worth $19.02 as of December 21, 2024 at a share price of $1.9. Whereas If you bought $1000 worth of BioVie Inc. (BIVI) shares 3 years ago, it would be worth $33.93 as of December 21, 2024 at a share price of $1.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
GlobeNewswire Inc.
Nov 20, 2024 1:00 PM GMT
CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanc
BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded
GlobeNewswire Inc.
Nov 04, 2024 1:00 PM GMT
CARSON CITY, Nev., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanc
BioVie Inc. Announces Closing of Registered Direct Offering
GlobeNewswire Inc.
Oct 29, 2024 8:05 PM GMT
CARSON CITY, Nev., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurolo